Known targets — ChEMBL curated mechanism
ABCC8ACEADORA1ADORA2AADORA2BADORA3ALDH5A1ALOX5ALOX5APATP4AATP4BBRAFCA1CA12CA2CA4CYSLTR1DHFRDPEP1EDNRAEDNRBESR2F10FDPSFGF1GABBR1GABBR2GABRA1GABRA2GABRA3GABRA4GABRA5GABRA6GABRB1GABRB2GABRB3GABRDGABREGABRG1GABRG2GABRG3GABRPGABRQGARTGNRHRGSC1HMGCRIMPDH1IMPDH2KCNJ11LY96NOD2NR3C1NS3NS4ANS5bP2RY1P2RY12P2RY2P2RY4P2RY6PBP2XPDE3APDE3BPDE4APDE4BPDE4CPDE4DPDK1PDK2PDK3PDK4PPARGPPATPTGIRPTGS1PTGS2RAF1RYR1RYR3SCN10ASCN11ASCN1ASCN2ASCN3ASCN4ASCN5ASCN7ASCN8ASCN9ASERPINC1SLC12A1SLC12A3SYKTHRATHRBTLR3TLR4TLR9TUBA1ATUBA1BTUBA1CTUBA3CTUBA3ETUBA4ATUBBTUBB1TUBB2ATUBB2BTUBB3TUBB4ATUBB4BTUBB6TUBB8TYMSVKORC1XDHblablaIMP-1blaOXA-33blaOXA-58blaT-3blaT-4blaT-5blaT-6dacAdacBdacCfolAfolPfolP1ftsIfusAgaggyrAgyrBmecAmrcAmrcBmrdApbp1apbp1bpbp2pbp2apbp2bpbp3pbp4pbpApbpBpbpCpbpFpolponBrplArplBrplCrplDrplErplFrplJrplKrplLrplMrplNrplOrplPrplQrplRrplSrplTrplUrplVrplWrplXrplYrpmArpmBrpmCrpmDrpmErpmFrpmGrpmHrpmIrpmJrpoArpoBrpoCrpoZrpsArpsBrpsCrpsDrpsErpsFrpsGrpsHrpsIrpsJrpsKrpsLrpsMrpsNrpsOrpsPrpsQrpsRrpsSrpsTrpsUykgMykgO
The experimentally established mechanism targets of None. The predicted profile below is derived independently by chemical similarity — agreement is a validation signal, a miss is honest.
Predicted protein targets (top 18)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CA4 known ✓ | P22748 | 4/20 | 0.44 |
| ▸ | CA1 known ✓ | P00915 | 3/20 | 0.41 |
| ▸ | FAHD1 | Q6P587 | 1/20 | 0.44 |
| ▸ | FFAR3 | O14843 | 3/20 | 0.43 |
| ▸ | HDAC3 | O15379 | 2/20 | 0.43 |
| ▸ | HDAC1 | Q13547 | 2/20 | 0.43 |
| ▸ | HDAC2 | Q92769 | 2/20 | 0.43 |
| ▸ | HDAC8 | Q9BY41 | 2/20 | 0.43 |
| ▸ | TDP1 | Q9NUW8 | 2/20 | 0.39 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.39 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.38 |
| ▸ | TSHR | P16473 | 1/20 | 0.38 |
| ▸ | NFKB1 | P19838 | 1/20 | 0.38 |
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 0.38 |
| ▸ | MEN1 | O00255 | 1/20 | 0.37 |
| ▸ | LDHA | P00338 | 1/20 | 0.37 |
| ▸ | BLM | P54132 | 1/20 | 0.37 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.37 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL447528 | 1.00 | CA4 (0.44) | CA4FAHD1FFAR3HDAC3HDAC1 | |
| Potassium Ion SCHEMBL305429 | 0.97 | FFAR3 (0.41) | CA4FAHD1FFAR3HDAC3HDAC1 | |
| Zinc Ion SCHEMBL138684 | 0.93 | FFAR3 (0.39) | CA4FAHD1FFAR3HDAC3HDAC1 | |
| SCHEMBL2139831 | 0.93 | FFAR3 (0.39) | CA4FAHD1FFAR3HDAC3HDAC1 | |
| SCHEMBL135448 | 0.93 | FFAR3 (0.39) | CA4FAHD1FFAR3HDAC3HDAC1 | |
| SCHEMBL2139837 | 0.93 | FFAR3 (0.39) | CA4FAHD1FFAR3HDAC3HDAC1 | |
| Zinc Ion SCHEMBL138682 | 0.93 | FFAR3 (0.39) | CA4FAHD1FFAR3HDAC3HDAC1 | |
| SCHEMBL135446 | 0.93 | FFAR3 (0.39) | CA4FAHD1FFAR3HDAC3HDAC1 | |
| SCHEMBL30561221 | 0.93 | FFAR3 (0.39) | CA4FAHD1FFAR3HDAC3HDAC1 | |
| Alcohol SCHEMBL9854483 | 0.88 | ALDH1A1 (0.35) | CA4FAHD1FFAR3HDAC3HDAC1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 35 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-12637481-B2 | Boronic acid derivatives and therapeutic uses thereof | QPEX BIOPHARMA, INC. (US) | 2026-05-26 | — | — | US | disclosed |
| US-12552815-B2 | Boronic acid derivatives and synthesis, polymorphic forms, and therapeutic uses thereof | QPEX BIOPHARMA, INC. (US) | 2026-02-17 | — | — | US | disclosed |
| US-12509475-B2 | Boronic acid derivatives and therapeutic uses thereof | QPEX BIOPHARMA, INC. (US) | 2025-12-30 | — | — | US | disclosed |
| US-20250064838-A1 | THERAPEUTIC USES OF PHARMACEUTICAL COMPOSITIONS COMPRISING CYCLIC BORONIC ACID ESTER DERIVATIVES | MELINTA SUBSIDIARY CORP. | 2025-02-27 | — | — | US | disclosed |
| US-20250034175-A1 | BORONIC ACID DERIVATIVES AND THERAPEUTIC USES THEREOF | QPEX BIOPHARMA, INC. | 2025-01-30 | — | — | US | disclosed |
| US-20250002508-A1 | BORONIC ACID DERIVATIVES AND SYNTHESIS, POLYMORPHIC FORMS, AND THERAPEUTIC USES THEREOF | QPEX BIOPHARMA, INC. | 2025-01-02 | — | — | US | disclosed |
| EP-3164406-B1 | BORONIC ACID DERIVATIVES AND THERAPEUTIC USES THEREOF | QPEX BIOPHARMA INC (US) | 2024-12-25 | — | — | EP | disclosed |
| US-12171772-B2 | Therapeutic uses of pharmaceutical compositions comprising cyclic boronic acid ester derivatives | MELINTA SUBSIDIARY CORP. (US) | 2024-12-24 | — | — | US | disclosed |
| US-20240307422-A1 | BORONIC ACID DERIVATIVES AND THERAPEUTIC USES THEREOF | QPEX BIOPHARMA INC (US) | 2024-09-19 | — | — | US | disclosed |
| EP-3139930-B1 | SALTS AND POLYMORPHS OF CYCLIC BORONIC ACID ESTER DERIVATIVES AND THERAPEUTIC USES THEREOF | MELINTA THERAPEUTICS INC (US) | 2024-08-14 | — | — | EP | disclosed |
| US-9115079-B2 | NDM inhibitor | MEIJI SEIKA PHARMA CO., LTD. (JP) | 2015-08-25 | — | — | US | disclosed |
| US-20140221330-A1 | NDM INHIBITOR | MEIJI SEIKA PHARMA CO., LTD. (JP) | 2014-08-07 | — | — | US | disclosed |
| EP-2737900-A1 | NDM INHIBITOR | Meiji Seika Pharma Co., Ltd. (JP) | 2014-06-04 | — | — | EP | disclosed |
| US-8697382-B2 | Method of identifying metallo-β-lactamase-producing bacteria | MEIJI SEIKA PHARMA CO., LTD. (JP) | 2014-04-15 | — | — | US | disclosed |
| US-20120071457-A1 | METALLO-BETA-LACTAMASE INHIBITORS | CHIKAUCHI KEN (JP) | 2012-03-22 | — | — | US | disclosed |
| US-20120064557-A1 | METHOD OF IDENTIFYING METALLO-BETA-LACTAMASE-PRODUCING BACTERIA | MEIJI SEIKA PHARMA CO., LTD. (JP) | 2012-03-15 | — | — | US | disclosed |
| EP-2415875-A1 | METHOD FOR IDENTIFICATION OF METALLO- B -LACTAMASE-PRODUCING BACTERIUM | Meiji Seika Pharma Co., Ltd. (JP) | 2012-02-08 | — | — | EP | disclosed |
| US-8093294-B2 | Bacterial infections; effective for recovering the activities of beta-lactam antibiotics; 2-ethyl-3-methylmaleic acid dimethyl ester; maleic acid derivatives and/or dihydrofuranyl derivatives | MEIJI SEIKA KAISHA, LTD. (JP) | 2012-01-10 | — | — | US | disclosed |
| EP-1941873-A1 | METALLO-BETA-LACTAMASE INHIBITOR | MEIJI SEIKA KAISHA LTD. (JP) | 2008-07-09 | — | — | EP | disclosed |
| US-20080090825-A1 | Metallo-beta-lactamase inhibitors | MEIJI SEIKA KAISHA, LTD. (JP) | 2008-04-17 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (11 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20080090825-A1 | Metallo-beta-lactamase inhibitors | ME1, MGAM, GAA | CA4 637/4885CA1 727/4885FAHD1 3228/4885 |
| US-20250002508-A1 | BORONIC ACID DERIVATIVES AND SYNTHESIS, POLYMORPHIC FORMS, AND THERAPEUTIC USES THEREOF | BLVRB, BBC3, BPGM | CA4 654/4885CA1 2696/4885FAHD1 3809/4885 |
| US-20240307422-A1 | BORONIC ACID DERIVATIVES AND THERAPEUTIC USES THEREOF | BCL6B, BCL6, BTD | CA4 212/4885CA1 1095/4885FAHD1 4238/4885 |
| US-20120071457-A1 | METALLO-BETA-LACTAMASE INHIBITORS | ME1, MGAM, GAA | CA4 637/4885CA1 727/4885FAHD1 3228/4885 |
| US-20250064838-A1 | THERAPEUTIC USES OF PHARMACEUTICAL COMPOSITIONS COMPRISING CYCLIC BORONIC ACID ESTER DERIVATIVES | BCL6B, BCL6, SLC10A2 | CA4 384/4885CA1 1340/4885FAHD1 4355/4885 |
| US-12509475-B2 | Boronic acid derivatives and therapeutic uses thereof | LBR, BLVRB, SRR | CA4 1228/4885CA1 1975/4885FAHD1 4675/4885 |
| US-12637481-B2 | Boronic acid derivatives and therapeutic uses thereof | BBC3, BLK, BRI3BP | CA4 545/4885CA1 3436/4885FAHD1 4192/4885 |
| US-20140221330-A1 | NDM INHIBITOR | MGAM, NQO1, NQO2 | CA4 2207/4885CA1 3782/4885FAHD1 1354/4885 |
| US-12171772-B2 | Therapeutic uses of pharmaceutical compositions comprising cyclic boronic acid ester derivatives | BCL6B, BCL6, SLC10A2 | CA4 384/4885CA1 1340/4885FAHD1 4355/4885 |
| US-12552815-B2 | Boronic acid derivatives and synthesis, polymorphic forms, and therapeutic uses thereof | BBC3, BLK, BRCA1 | CA4 529/4885CA1 3661/4885FAHD1 2837/4885 |
| US-20250034175-A1 | BORONIC ACID DERIVATIVES AND THERAPEUTIC USES THEREOF | BTD, BLK, BCL6B | CA4 361/4885CA1 1408/4885FAHD1 4363/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.